US FDA is urging providers to consider alternatives to paclitaxel-coated devices for the treatment of peripheral arterial disease (PAD) after an agency analysis found the drug-eluting stents and balloons were linked to a higher patient mortality rate.
FDA initially issued an alert about the possible long-term mortality risk in January, after a meta-analysis of randomized trials published in the Journal of the American Heart Association detected the...